Syndex was founded by Geoff Smith in 2022.

Who are Syndex's investors?

Syndex's investors include OMX Ventures.

How much funding has Syndex raised?

Syndex has disclosed $15.5M raised across 1 round.

Where is Syndex headquartered?

Syndex is headquartered in Santa Monica, US.

Syndex

Santa Monica, US · Founded 2022 · 1 known investors

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

Biotech Deep Tech Medical Devices

Founders & leadership

Syndex was founded in 2022 by Geoff Smith.

Geoff SmithFounder & CEO

Jason BetleyChief Product Officer

Investors · 1

OMX VenturesLincolnshire

Reported raises · per SEC filings

Form D private placements

$15.5M disclosed across 1 round · 2025

▶$15.5MraisedMar 2025 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Geoff Paul SmithExecutive Officer, Director

Offering amount: $15.5M
Amount sold: $15.5M
First sale: Feb 2025
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 7

by search overlap

Thumbnail for SyntheX10 shared keywordsSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.

Syenex6 shared keywordsSyenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Syntax4 shared keywordsSyntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.

Senex Biotechnology4 shared keywordsSenex Biotechnology develops cancer and chronic disease therapies by targeting aging-related biological pathways identified through functional genomics. The company focuses on oncology indications including ovarian, breast, and prostate cancers.

SOSV Visit SOSV3 shared keywordsSOSV is a venture capital firm that provides pre-seed funding (up to $550,000) to founders in deep technology sectors including life sciences, robotics, industrial automation, energy transition, and medical technology. The firm operates accelerator programs in New York City, San Francisco, and Newark, NJ, and does not invest in enterprise software, fintech, blockchain, crypto, cybersecurity, or ecommerce.

Synlogic3 shared keywordsSynlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.

Companies competing with Syndex for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Syndex do?: Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.
Who founded Syndex?: Syndex was founded by Geoff Smith in 2022.
Who are Syndex's investors?: Syndex's investors include OMX Ventures.
How much funding has Syndex raised?: Syndex has disclosed $15.5M raised across 1 round.
Where is Syndex headquartered?: Syndex is headquartered in Santa Monica, US.